View Older Stories View More Recent Stories

Sep 21, 2017 10:00AM National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views
Sep 21, 2017 10:00AM National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views
Sep 21, 2017 06:59AM New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors
Sep 21, 2017 06:23AM Merck KGaA, Pfizer (PFE) Report European Commission Approval for Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 21, 2017 03:13AM European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 19, 2017 01:19PM Pfizer (PFE) Confirms Tied FDA Panel Vote on SUTENT
Sep 19, 2017 01:15PM Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery
Sep 11, 2017 07:04AM Pfizer (PFE) Presents OS Data of XALKORI in Patients with ALK-Positive Advanced NSCLC
Sep 11, 2017 07:00AM Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Sep 11, 2017 05:56AM Pfizer (PFE) Reports Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin (trastuzumab) at ESMO 2017
Sep 10, 2017 03:15AM Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress
Sep 1, 2017 11:38AM Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)
Aug 31, 2017 08:54AM Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease
Aug 29, 2017 08:40AM Pfizer (PFE) & Bristol-Meyers Squibb (BMY) Report Positive Real-World Data for Eliquis (Apixaban) Compared to Warfrin in Patients Over 65 with NVAF
Aug 29, 2017 08:21AM Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valv
Aug 29, 2017 07:02AM Pfizer (PFE) Reports FDA & EMA Regulatory Submissions for BOSULIF
Aug 29, 2017 07:00AM U.S. FDA and European Medicines Agency Accept Regulatory Submissions for BOSULIF® (bosutinib) for the Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
Aug 28, 2017 05:42AM Pfizer (PFE) & Bristol-Myers Squibb (BMY) Report Results of Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis
Aug 28, 2017 05:00AM Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion
Aug 28, 2017 02:30AM Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvul
Aug 25, 2017 08:02AM Sangamo Biosciences (SGMO), Pfizer (PFE) Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525
Aug 25, 2017 08:00AM Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A
Aug 24, 2017 08:04AM Pfizer (PFE) Announces Launch of Hemocraft & HemMobile, Innovative Technologies for People Living with Hemophilia
Aug 24, 2017 08:00AM Pfizer Rare Disease Launches Two First-of-Its-Kind Innovative Technologies for People Living with Hemophilia at National Hemophilia Foundation Annual Meeting
Aug 18, 2017 07:02AM Bristol-Myers Squibb (BMY), Pfizer (PFE) to Highlight Commitment to Reducing Risk of Stroke Caused by NVAF and Treating DVT/PE at ESC Congress
Aug 18, 2017 06:59AM Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) a
Aug 17, 2017 02:03PM Pfizer Granted U.S. FDA Approval for BESPONSA (inotuzumab ozogamicin)
Aug 17, 2017 01:57PM Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)
Aug 3, 2017 02:15PM Pfizer (PFE) Confirms FDA Advisory Committee Vote in Favor of XELJANZ
Aug 3, 2017 02:10PM FDA Advisory Committee Votes in Favor of XELJANZ® (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis
Jul 24, 2017 08:30AM Pfizer (PFE) Reports Positive Top-Line Results from Comparative REFLECTIONS B7391003 Study for PF-06439535
Jul 24, 2017 08:30AM Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab)
Jul 21, 2017 07:52AM Merck KGaA, Pfizer (PFE) Report EMA's CHMP Issued Positive Opinion for Avelumab for Treatment of mMCC
Jul 21, 2017 07:50AM EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Jul 20, 2017 03:18PM Merck (MRK) and Pfizer (PFE) Collaborate with Corning (GLW) to Modernize Pharmaceutical Glass Packaging
Jul 20, 2017 03:15PM Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging
Jul 20, 2017 05:54AM Pfizer (PFE) Announces License Agreement with Basilea Pharma for Commercialization Rights in Europe for CRESEMBA (isavuconazole)
Jul 20, 2017 01:23AM Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole), A Novel Treatment For Potentially Life-Threatening Fungal Infections Among Immunoc
Jul 20, 2017 01:15AM Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
Jul 13, 2017 08:02AM Pfizer (PFE) Announces FDA Accepts sNDA for XELJANZ for Treatment of Adult Patients with Moderately to Severely Active UC
Jul 13, 2017 08:00AM Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Jul 11, 2017 04:34PM Pfizer (PFE) Reports Favorable FDA Advisory Committee Vote on MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia
Jul 11, 2017 04:32PM FDA Advisory Committee Votes in Favor of Pfizer’s MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia
Jun 27, 2017 09:00AM Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri
Jun 22, 2017 04:05PM Pfizer Declares 32-Cent Third-Quarter 2017 Dividend
Jun 19, 2017 08:04AM Pfizer (PFE) Commences Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine
Jun 19, 2017 08:00AM Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine
Jun 16, 2017 06:16AM Pfizer (PFE) Announces Results from XELJANZ ORAL Strategy Study Published in The Lancet and Presented at EULAR
Jun 16, 2017 04:35AM Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress
Jun 14, 2017 01:20PM Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients
View More Recent Stories View Older Stories